BR112023018799A2 - Derivados de purina como agentes anticâncer - Google Patents
Derivados de purina como agentes anticâncerInfo
- Publication number
- BR112023018799A2 BR112023018799A2 BR112023018799A BR112023018799A BR112023018799A2 BR 112023018799 A2 BR112023018799 A2 BR 112023018799A2 BR 112023018799 A BR112023018799 A BR 112023018799A BR 112023018799 A BR112023018799 A BR 112023018799A BR 112023018799 A2 BR112023018799 A2 BR 112023018799A2
- Authority
- BR
- Brazil
- Prior art keywords
- purine derivatives
- cancer agents
- formula
- ring
- compounds
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title abstract 2
- 150000003212 purines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162460P | 2021-03-17 | 2021-03-17 | |
| PCT/US2022/020700 WO2022197892A1 (en) | 2021-03-17 | 2022-03-17 | Purine derivatives as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023018799A2 true BR112023018799A2 (pt) | 2023-12-12 |
Family
ID=81327909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023018799A BR112023018799A2 (pt) | 2021-03-17 | 2022-03-17 | Derivados de purina como agentes anticâncer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240059689A1 (https=) |
| EP (1) | EP4308566A1 (https=) |
| JP (1) | JP2024511996A (https=) |
| KR (1) | KR20240006509A (https=) |
| CN (1) | CN117425656A (https=) |
| AU (1) | AU2022238886A1 (https=) |
| BR (1) | BR112023018799A2 (https=) |
| CA (1) | CA3212292A1 (https=) |
| IL (1) | IL305991A (https=) |
| MX (1) | MX2023010909A (https=) |
| WO (1) | WO2022197892A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312642A (en) | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| EP4430049A4 (en) * | 2021-11-12 | 2025-12-17 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
| TW202509030A (zh) | 2023-05-08 | 2025-03-01 | 美商譚格醫療公司 | 化合物及使用方法 |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| CN117024253A (zh) * | 2023-08-14 | 2023-11-10 | 江西阿尔法高科药业有限公司 | 一种药用级麝香草酚特定杂质的制备方法 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| TW202539659A (zh) | 2024-01-10 | 2025-10-16 | 美商維瑞斯治療股份有限公司 | Ｄｎａ損傷修復途徑的新穎抑制劑 |
| WO2025256544A1 (zh) * | 2024-06-11 | 2025-12-18 | 福建盛迪医药有限公司 | 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法 |
| CN119751316A (zh) * | 2024-12-20 | 2025-04-04 | 江南大学 | 一种1-苯基三氟甲基n-（氟磺酰基）氨基甲酸酯化合物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI378933B (en) * | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| JP2011236198A (ja) * | 2010-04-13 | 2011-11-24 | Daiichi Sankyo Co Ltd | モルホリノプリン誘導体 |
| CN108473495B (zh) * | 2015-11-20 | 2022-04-12 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| US11485736B2 (en) * | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
-
2022
- 2022-03-17 WO PCT/US2022/020700 patent/WO2022197892A1/en not_active Ceased
- 2022-03-17 IL IL305991A patent/IL305991A/en unknown
- 2022-03-17 JP JP2023557285A patent/JP2024511996A/ja active Pending
- 2022-03-17 CN CN202280035481.2A patent/CN117425656A/zh active Pending
- 2022-03-17 BR BR112023018799A patent/BR112023018799A2/pt unknown
- 2022-03-17 AU AU2022238886A patent/AU2022238886A1/en not_active Abandoned
- 2022-03-17 CA CA3212292A patent/CA3212292A1/en active Pending
- 2022-03-17 MX MX2023010909A patent/MX2023010909A/es unknown
- 2022-03-17 EP EP22717473.7A patent/EP4308566A1/en active Pending
- 2022-03-17 KR KR1020237035424A patent/KR20240006509A/ko active Pending
-
2023
- 2023-09-15 US US18/468,385 patent/US20240059689A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240006509A (ko) | 2024-01-15 |
| IL305991A (en) | 2023-11-01 |
| CN117425656A (zh) | 2024-01-19 |
| MX2023010909A (es) | 2024-02-13 |
| JP2024511996A (ja) | 2024-03-18 |
| AU2022238886A1 (en) | 2023-09-14 |
| WO2022197892A1 (en) | 2022-09-22 |
| EP4308566A1 (en) | 2024-01-24 |
| CA3212292A1 (en) | 2022-09-22 |
| US20240059689A1 (en) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023018799A2 (pt) | Derivados de purina como agentes anticâncer | |
| CL2019002297A1 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
| MX2018005890A (es) | Composiciones para tratar atrofia muscular espinal. | |
| ECSP19041050A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| CL2011000777A1 (es) | Compuestos derivados de imidazopiridazina, inhibidor de proteína quinasa; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, psoriasis, artritis reumatoide, angiogenesis, entre otras. | |
| CY1116143T1 (el) | Παραγωγα χρωμενονης με αντικαρκινικη δραση | |
| CO2018000660A2 (es) | Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol | |
| CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
| DOP2015000082A (es) | Inhibidores no nucleósidos de la transcriptasa inversa | |
| UY36212A (es) | Moduladores de receptores tipo toll para el tratamiento del vih | |
| UY37168A (es) | Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles | |
| UY36677A (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| UY32379A (es) | Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones. | |
| CR10614A (es) | Derivados heterociclicos fusionados y metodos de uso | |
| CU20090180A7 (es) | Derivados de piridina | |
| GT201400031A (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
| CL2021002309A1 (es) | Compuestos útiles en la terapia del vih | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| CO2017009994A2 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
| DOP2015000214A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| MX2017011978A (es) | Analogos deuterados de etifoxina, sus derivados y usos de estos. | |
| MA40250A (fr) | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k |